Repotrectinib safety study in Japanese children with NTRK fusion tumors
Treatments studied
Part of Cancer clinical trials.
This study tracks the safety and effects of the drug repotrectinib in children aged 4 to under 18 with certain tumors that have a specific genetic change (NTRK fusion). The goal is to see how well the drug works in everyday medical practice in Japan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Being aged between 4 and under 18 years old
- Having been diagnosed with a solid tumor that is advanced or has come back after treatment
- Your tumor must have a specific genetic change called NTRK fusion
- You must be receiving repotrectinib as part of your regular care in Japan, not through a study
- Repotrectinib must be given for an approved use, not for an unapproved condition
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests repotrectinib, a targeted medicine, in children and young adults whose tumors have specific gene changes involving ROS1 or NTRK. It may help shrink advanced cancers that carry these gene alterations.
This trial is a safety follow-up study for people who are already being treated with repotrectinib in Korea. It looks at how well the drug works and what side effects may occur in patients with ROS1-positive lung cancer or NTRK-positive solid tumors.
This trial studies repotrectinib, a targeted medicine, in people with advanced solid tumors that have specific gene rearrangements (ALK, ROS1, or NTRK). It may help shrink tumors or control cancer growth based on the patient’s tumor genetic result.
This early-phase study tests repotrectinib (a targeted anti-cancer pill) combined with chemotherapy in children and young adults whose solid tumors have come back or did not respond to standard treatment. The goal is to see how safe the treatment is and whether it can shrink tumors.
This trial tests an oral targeted therapy called repotrectinib in people with advanced non-small cell lung cancer (NSCLC) that has a change in the ROS1 gene. It is designed for patients who are either 70 or older, or have a lower performance status (ECOG 2 or higher), meaning they may be more frail or have more symptoms. The goal is to see if repotrectinib can help shrink or control the cancer.
This trial provides access to repotrectinib, a targeted therapy for certain cancers, when no other treatment options are available. It aims to give patients a chance to try this medication under a special program.
Hear when a new NTRK Fusion-positive Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.